» Articles » PMID: 19079360

Active and Zymogen Forms of Granzyme B Are Constitutively Released from Cytotoxic Lymphocytes in the Absence of Target Cell Engagement

Overview
Publisher Wiley
Date 2008 Dec 17
PMID 19079360
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Granzyme B (GrB) plays a well-established intracellular role in cytotoxic lymphocyte (CL)-mediated killing of abnormal cells; however, emerging evidence suggests that it participates in extracellular matrix remodeling and target cell destruction through anoikis. As these processes require the release of GrB from the CL into the extracellular environment, we examined the secretion of GrB from natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). We found that a proportion of GrB is constitutively secreted by both CTLs and NK cells in the absence of target cell engagement. In NK cells, the protease is primarily released in an active form through secretory granules. By contrast, T lymphocytes primarily secrete inactive GrB zymogen, bypassing the granules. The release of GrB through two routes from unconjugated CLs suggests that it functions outside the cell and may contribute to pathology in cases of immune dysregulation, such as familial hemophagocytic lymphohistiocytosis (FHL). Our findings also predict the existence of an extracellular activator of GrB.

Citing Articles

Potential implications of granzyme B in keloids and hypertrophic scars through extracellular matrix remodeling and latent TGF-β activation.

Aubert A, Goeres J, Liu A, Kao M, Richardson K, Jung K Front Immunol. 2025; 15:1484462.

PMID: 39885984 PMC: 11779620. DOI: 10.3389/fimmu.2024.1484462.


Granzyme B cleaves tenascin-C to release its C-terminal domain in rheumatoid arthritis.

Aubert A, Liu A, Kao M, Goeres J, Richardson K, Nierves L JCI Insight. 2024; 9(23).

PMID: 39475853 PMC: 11623945. DOI: 10.1172/jci.insight.181935.


Granzyme serine proteases in inflammation and rheumatic diseases.

Aubert A, Jung K, Hiroyasu S, Pardo J, Granville D Nat Rev Rheumatol. 2024; 20(6):361-376.

PMID: 38689140 DOI: 10.1038/s41584-024-01109-5.


Granzymes in health and diseases: the good, the bad and the ugly.

Cigalotto L, Martinvalet D Front Immunol. 2024; 15():1371743.

PMID: 38646541 PMC: 11026543. DOI: 10.3389/fimmu.2024.1371743.


Potential role of extracellular granzyme B in wet age-related macular degeneration and fuchs endothelial corneal dystrophy.

Dubchak E, Obasanmi G, Zeglinski M, Granville D, Yeung S, Matsubara J Front Pharmacol. 2022; 13:980742.

PMID: 36204224 PMC: 9531149. DOI: 10.3389/fphar.2022.980742.